Search

Your search for "nmrd" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate in H.C. Wainwright Global Hybrid Investment Conference

May 19, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, and its CEO Dr. Faz Chowdhury will be attending the upcoming H.C. Wainwright Global Hybrid Investment Conference. The conference is slated for May 23–26, 2022, in Miami Beach, Florida. Chowdhury has been invited […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) UK licensee, MySugarWatch, Begins Direct-to-Consumer Campaign in Daily Mail

May 17, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that MySugarWatch, its UK licensee is launching a direct-to-consumer campaign in “Daily Mail,” one of the United Kingdom’s largest daily newspaper. The campaign is part of MySugarWatch’s large-scale awareness efforts focused on […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Launch of Physician-Focused Ads as Part of Large-Scale Campaign Around sugarBEAT(R)

May 3, 2022

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that its U.K. licensee, MySugarWatch, as part of a large scale awareness campaign for the company’s sugarBEAT non-invasive continuous glucose monitor, has launched a series of ads in […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at Planet MicroCap Showcase 2022

April 25, 2022

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that it will be presenting at the Planet MicroCap Showcase 2022, which is slated to take place from May 3-5, 2022, at the Bally’s Hotel & Casino in […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Technologies Stand Distinct

April 1, 2022

Nemaura Medical (NASDAQ: NMRD) recently launched its MiBoKo metabolic health and wellness program, offering a distinct competitive advantage with AI-powered monitoring devices that are non-invasive, easy to wear and cost-effective. “Sensors developed by Nemaura stand apart from competitor devices that employ microneedles coated with enzymes and polymers — some of which require insertion for up […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming Maxim Group 2022 Virtual Growth Conference

March 25, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be attending and participating at this month’s Maxim Group 2022 Virtual Growth Conference. NMRD CEO Dr. Faz Chowdhury will be providing an overview of the company that will […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Valuable AI-Powered Insights to Diabetes Market

March 22, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company developing and commercializing non-invasive wearable diagnostic devices, is positioned to offer innovative solutions to a rapidly growing market. According to a recent report released by the International Diabetes Federation (“IDF”), diabetes is “spiraling out of control.” According to the report, 537 million adults live with diabetes, a […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Commercialization Phase of Its Corporate Development, Recognizes First-Ever Revenues

March 18, 2022

Nemaura Medical (NASDAQ: NMRD) recently announced its Q3 FY 2022 results for the three months ended Dec. 31, 2021. The company reported revenues of $183,628 due to the initial shipments made over the past quarter of sugarBEAT(R) CGM devices to MySugarWatch, the company’s U.K. licensee. The order marked the inaugural revenues in Nemaura Medical’s history, […]

News Articles

Metabolic Health Diseases Rising Globally, Nemaura Medical Inc. (NASDAQ: NMRD) Aims to Disrupt Market with Non-Invasive, Cost-Effective IoT Devices, Mikobo Coaching Program

March 17, 2022

Metabolic disease cases rising globally, diseases include diabetes, dementia, cardiovascular conditions, stroke Companies in diagnostic space posting record revenues, double-digit YOY increases Nemaura Medical aims to disrupt the market with Mikobo program’s non-invasive sensor technology, companion mobile application and coaching programs Competitor devices use microneedles coated with enzymes and polymers that can cause discomfort, trauma, […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Revolutionary sugarBEAT(R) CGM Device Met with Early Success

March 11, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company, has sought to develop and offer economical, compact and convenient non-invasive devices that could alleviate the pain associated with frequent skin pricking among diabetic patients. The devices also simultaneously promote routine glucose testing in a bid to control blood glucose levels more effectively. Nemaura offers two flagship […]

News Articles

Nemaura Medical Inc.’s (NASDAQ: NMRD) sugarBEAT(R) Wearable CGM Device Targets Billion-Dollar Global Diabetes Market

March 2, 2022

Global diabetes-related healthcare expenses are estimated at $966 billion in 2021 A recent report reveals 537 million adults currently live with diabetes, projected to rise to 643 million by 2030 and 783 million by 2045  Glucose intake is an important factor in diabetes management, prevention and reversal NMRD’s sugarBEAT(R) wearable is a non-invasive, flexible CGM […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Recognized as Innovator of the Year, Awarded Top Honors for Innovation in MedTech, Life Sciences

February 28, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its receipt of the top award as Innovator of the Year at the LeicestershireLive Innovation Awards 2022 held on Feb. 24, 2022. In addition, the company was awarded top honors […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Publishes 3QFY2022 Results; Company Reports its Inaugural Quarterly Revenues

February 25, 2022

Nemaura Medical has recently reported its 3QFY2022 (4QCY2021) results, with the company recognizing its inaugural revenues of $183,628 over the quarter The company also announced that it held $23 million in cash reserves as of the end of the quarter, which should amply cover its cash requirements over the coming months Nemaura Medical seized upon […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Producing What Was Thought to Be Implausible

February 23, 2022

Nemaura Medical (NASDAQ: NMRD) has long focused on its corporate mission to develop non-invasive wearable diagnostic devices designed to help diabetic and near-diabetic patients monitor blood glucose levels by measuring blood markers at the surface of the skin. Its revolutionary sugarBEAT(R) constant glucose monitoring (“CGM”) device provides users with non-invasive glucose monitoring. Recently, the company […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Seeks to Provide Non-Invasive Glucose Monitoring Solutions to Millions of Patients Worldwide

February 17, 2022

Over 420 million people around the globe currently have diabetes, with the figure set to rise by 55% over the next 25 years Millions of patients required to measure their blood glucose levels daily to accurately determine their insulin dosage amounts Nemaura Medical has launched two constant glucose monitoring solutions – the SugarBEAT(R) device as […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Reports Financial Results, Business Updates for Q3 2022

February 14, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has released its Q3 financial results and business updates. The company noted that, for the three-month period ending Dec. 31, 2021, highlights included the shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its […]

News Articles

Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference

NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022 Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion NMRD’s sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to use NMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Appoints New COO in Readiness for Manufacturing and Distribution Scale-Up, Commercialization Phase of Growth

February 11, 2022

Nemaura Medical (NASDAQ: NMRD) recently appointed Dr. Arash Ghadar as its chief operating officer. Dr. Ghadar brings decades of health care and technical experience to Nemaura, including from his previous role as technical director at Datalink Electronics and his current director role at Medilink Midlands. “Ash will play an important role at Nemaura as we […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Set to Capitalize on Glucose Monitoring Sector’s Exponential Growth Rate

February 9, 2022

The blood glucose monitoring system sector is expected to grow to a value of $27.2 billion by 2026, expanding at a CAGR of 9.6% between 2021-2026 Over 420 million people around the globe currently have diabetes, with the American Diabetes Association recommending that all adults screen for the condition every three years Nemaura Medical has […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc.’s (NASDAQ: NMRD) Miboko Launch Leveraging ‘Most Reliable Gateway Toward Wider Adoption of Preventative Health Maintenance Practices’

February 3, 2022

Nemaura Medical (NASDAQ: NMRD) recently announced it would launch Miboko, its new metabolic health program, for employers and insurers. “The Miboko application, a service offering that has been in development over the past 18 months, uses a non-invasive glucose sensor to measure and monitor users’ blood sugar levels, which are based on glucose tolerance or […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Appoints Technical Healthcare Specialist Dr. Arash Ghadar as COO

January 28, 2022

NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experience Dr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certification NMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, recently completed initial shipment to UK licensee MySugarWatch Limited MySugarWatch Limited aims to market devices […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Marks History Making Milestone with Initial Shipment of CGM Devices

January 27, 2022

Nemaura Medical (NASDAQ: NMRD) is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible and affordable continuous glucose monitoring (“CGM”) device. “As part of its marketing strategy, NMRD recently completed an initial shipment of sugarBEAT devices to MySugarWatch Limited, its U.K. licensee. MySugarWatch Limited intends to market sugarBEAT via a subscription-based diabetes coaching and […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Commence Rollout of Their Miboko Application; Company Targets Employers & Insurers to Ensure Broad Commercial Distribution

January 24, 2022

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently announced the rollout of its Miboko application by targeting insurers and employers In 2019, over $760 billion was spent on diabetes-related health care, equating to $9,000 per diabetic patient compared to $1,600 for a non-diabetic individual The Miboko […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Firmly Positioned in Growing Diabetes Tech Market With Recent CGM Shipment to UK Licensee

January 20, 2022

Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS  Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Launches Miboko – a New Metabolic Health Program

January 13, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of Miboko for employers and insurers. Miboko is a new metabolic health program using a non-invasive glucose sensor along with an AI mobile application. The company, aligned with […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names Industry Veteran as COO

January 10, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has appointed Dr. Arash (Ash) Ghadar as chief operating officer. Currently a non-executive director at Medilink Midlands, Ghadar served for 10 years as the technical director of London-based Datalink Electronics (Datalink), where he […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at H.C. Wainwright Bioconnect Conference

January 7, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Dr. Faz Chowdhury will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference. The event is slated to take place on Jan. 10-13, 2022, […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Marks True Milestone in Development, Growth

January 4, 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently completed the initial shipment of its sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited. “MySugarWatch will market the sugarBEAT product under the MySugarWatch(R) brand and has developed […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Bringing Solutions to Empower People to Take Charge of Their Health, Well-Being

December 29, 2021

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved to […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Complete Initial Shipment of sugarBEAT(R) Devices to UK Licensee

December 22, 2021

Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licensee The initial shipment, which comprised 5,000 CGM devices and 200,000 sensors, is expected to result in follow-on monthly orders of up to 2 million sensors and 15,000 CGM devices over the next two years Following […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Positioned to Benefit from Growth in CGM Market

December 13, 2021

Nemaura Medical (NASDAQ: NMRD) has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and health care observations. With the global continuous glucose monitoring (“CGM”) devices market expected to reach $19.04 billion in 2028 from $4.11 billion in 2020, according to an analysis by Reports and […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Initial Shipment of CGM Devices to MySugarWatch Licensee

December 7, 2021

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that it has completed its initial shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited, previously DB Ethitronix Limited. According to the update, MySugarWatch will […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Helping Diabetic Individuals Safeguard Themselves From COVID-19

1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing Nemaura Medical is a medical technology company focused […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

December 2, 2021

NMRD releases fiscal Q2-2021 results, provides business update Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector  Nemaura Medical (NASDAQ: […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) CEO to Present at Benzinga Global Small Cap Conference

November 30, 2021

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Faz Chowdhury, Ph.D., will present at the Benzinga Global Small Cap Conference. The event is scheduled to be held virtually from Dec. 8-9, 2021. Dr. Chowdhury will […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market

November 18, 2021

The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028 The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growth Nemaura Medical’s sugarBEAT device allows individuals to make adjustments to diet and activity that can significantly change their lives According to a recent […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2 2022 Financial, Business Report

November 15, 2021

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has reported its financial and business updates for the second quarter of FY2022, the period ended Sept. 30, 2021. Notable highlights include the launch of Miboko, the company’s beta mass-market metabolic health […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Extending Proprietary Technology, Programs Beyond Traditional Diabetes Market

November 9, 2021

Nemaura Medical (NASDAQ: NMRD), a cutting-edge medical technology company, recently conducted the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI-based mobile application. The MiBoKo application is designed to measure and monitor the user’s metabolic health scores based on glucose tolerance and insulin resistance. […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Participation at Diabetes Technology Society Conference

November 4, 2021

Nemaura Medical (NASDAQ: NMRD) CEO Faz Chowdhury, PhD, will be presenting at annual meeting of the Diabetes Technology Society. The two-day meeting is slated for Nov. 5–6, 2021, with virtual workshops on Thursday, Nov. 4; Chowdury’s presentation is scheduled for Nov. 4,  at 2 p.m. ET. The aim of the Diabetes Technology Society meeting is […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Stands Distinct in Patient Support

October 28, 2021

Nemaura Medical (NASDAQ: NMRD), a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, pays close attention to essential information and research that impacts the successful implementation of its solutions. Recently, the company tweeted about a study published by Dove Medical Press that included a survey of 105 participants with […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).